To play this presentation please log in.
Don't have an account?
Sign up for free and get access to 400+ programs, live events, CME/CNE evaluations, bookmarks, watch history, and more.
Faculty
Faculty
Alexander E Drilon
MD
Memorial Sloan-Kettering Cancer Center, New York, New York
Chief, Early Drug Development Service, Attending Physician, Thoracic Oncology Service
Weill Cornell Medical College, New York, New York
Professor
TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of non-small cell lung cancer.
PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with non-small cell lung cancer.
DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of novel therapies for non-small cell lung cancer and the management of associated treatment-related toxicities in order to educate, counsel and assist patients and their families in decision-making.
At the end of the activity, learners will also be able to
- Appreciate the incidence and clinical relevance of ROS1 gene alterations in metastatic non-small cell lung cancer (NSCLC), and recognize optimal approaches to identify these actionable abnormalities.
- Assess the pharmacologic similarities and differences among the various FDA-approved ROS1-targeted tyrosine kinase inhibitors (TKIs), and recognize the implications for the efficacy and tolerability of these agents.
- Understand published research findings and current guideline recommendations in order to counsel patients with ROS1-positive NSCLC regarding the selection and sequencing of therapy.
- Review available clinical trial data evaluating the efficacy and safety of ROS1 TKIs for patients with ROS1-positive NSCLC, and educate individuals regarding the benefits and risks of this therapeutic strategy.
- Recognize the spectrum, frequency, severity and optimal management of toxicities associated with ROS1-targeted TKIs to facilitate the safe and effective use of these agents.
ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.
CREDIT DESIGNATION STATEMENT
This educational activity for 1 contact hour is provided by RTP during the period of September 2026 to September 2027.
This activity is awarded 1 ANCC pharmacotherapeutic contact hour.
ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONU2026/TargetedLung/ILNA.
ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.
PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
FOR SUCCESSFUL COMPLETION
To receive credit for this activity, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better and fill out the evaluation.
CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
Dr Drilon is on advisory committees with Bayer HealthCare Pharmaceuticals, EcoR1 Capital LLC, Ellipses Pharma, Nuvalent, Nuvation Bio Inc and Zymeworks Inc; has consulting agreements with Bayer HealthCare Pharmaceuticals, Boundless Bio, Bristol Myers Squibb, Enlaza Therapeutics, Nuvalent, Nuvation Bio Inc, Regeneron Pharmaceuticals Inc, Treeline Biosciences and Two River; has contracted research with Foundation Medicine, GSK, Taiho Oncology Inc and Teva Oncology; holds a copyright for Selpercatinib-Osimertinib (US 18/041,617, pending); has received food/beverages from Boehringer Ingelheim Pharmaceuticals Inc, Merck and Puma Biotechnology Inc; holds stock options — private companies in Treeline Biosciences; and has nonrelevant financial relationships with UpToDate and Wolters Kluwer. All of these relevant financial relationships have been mitigated.
EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop NCPD activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.
RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.
This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
This activity is supported by an educational grant from Nuvation Bio Inc.
Release date: September 2026
Expiration date: September 2027
There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.
Bazhenova L et al. Taletrectinib in TKI-naïve patients with ROS1+ NSCLC: Updated data from TRUST-I and TRUST-II. AACR 2026;Abstract CT300.
Cho BC et al. Repotrectinib in patients with ROS1 fusion-positive (ROS1+) NSCLC: Long-term follow-up from the phase 1/2 TRIDENT-1 trial. World Conference on Lung Cancer 2025;Abstract MA02.03.
Desilets A et al. Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions. Cancer 2025;131(Suppl 1):e35784. Abstract
Drilon AE et al. Pivotal ARROS-1 efficacy and safety data: Zidesamtinib in TKI pre-treated patients with advanced/metastatic ROS1+ NSCLC. World Conference on Lung Cancer 2025;Abstract PL02.15.
Drilon AE et al. Repotrectinib in ROS1 fusion–positive non–small-cell lung cancer. N Engl J Med 2024;390(2):118-31. Abstract
Krebs MG et al. Updated efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC. ESMO 2024;Abstract 1290P.
Liu G et al. Taletrectinib in TKI-pretreated patients with ROS1+ non-small cell lung cancer: Updated data from TRUST-I and TRUST-II. AACR 2026;Abstract CT244.
Pérol M et al. Taletrectinib in ROS1+ non-small cell lung cancer: TRUST. J Clin Oncol 2025;43(16):1920-9. Abstract
Peters S et al. Entrectinib in ROS1-positive advanced non-small cell lung cancer: The phase 2/3 BFAST trial. Nat Med 2024;30(7):1923-32. Abstract